BULLISHWHALES
BullishWhales · Analysts · Analyst Profile
BW Score Rank#172 of 347

Jeff Jones

Oppenheimer · Equity Research Analyst
ProvisionalRating since 2022No new ratings since May 2025

Analyst rating accuracy & track record

Jeff Jones is an equity research analyst at Oppenheimer. Bullish Whales has scored 35 of their stock calls across 13 companies. Their picks beat their sector 32% of the time over the next 12 months, and their price targets were reached 25% of the time within a year.

Win % vs sector
32%
PT Hit % (12mo)
25%
Avg sector-excess
−6.8%
Scored calls
35
Tickers
13
Tier
Provisional

Track record

Bullish Whales has scored 35 of Jeff Jones's stock calls across 13 companies, dating back to 2022. Their rated stocks beat their own sector 32% of the time over the next 12 months. On a typical call, a Jones pick returned −6.8% more than its sector over the following year.

Of the scored calls, 35 were bullish (Buy). Most of their coverage sits in Healthcare. Every number on this page is an estimate from our own data. It is for education only and is not investment advice.

Coverage & ratings

Ratings & price targets

StockRatingPrice targetRated12-mo vs sectorPT hit
CMMBChemomab Therapeutics Ltd DRC
Buy$10.00May 2025−81.2%Miss
ALMSAlumis Inc
Buy$25.00May 2025+296.0%Hit
CRVSCorvus Pharmaceuticals Inc
Buy$17.00May 2025+282.8%Hit
ZURAZura Bio Limited Class A Ordinary Shares
Buy$17.00May 2025+276.0%Miss
IMCRImmunocore Holdings Ltd
Buy$86.00May 2025−5.9%Miss
CRBPCorbus Pharmaceuticals Holding
Buy$56.00May 2025+53.6%Miss
CRVSCorvus Pharmaceuticals Inc
Buy$15.00Mar 2025+315.2%Hit
ZURAZura Bio Limited Class A Ordinary Shares
Buy$19.00Mar 2025+343.4%Miss
ALMSAlumis Inc
Buy$32.00Jan 2025+220.5%Miss
CLRBCellectar Biosciences Inc
Buy$12.00Nov 2024−102.4%Miss
CMMBChemomab Therapeutics Ltd DRC
Buy$11.00Nov 2024−69.4%Miss
CRVSCorvus Pharmaceuticals Inc
Buy$14.00Nov 2024−13.7%Miss
CLRBCellectar Biosciences Inc
Buy$14.00Oct 2024−85.5%Miss
AVBPArriVent BioPharma, Inc. Common Stock
Buy$39.00Sep 2024−15.5%Miss
CRBPCorbus Pharmaceuticals Holding
Buy$88.00Aug 2024−71.1%Miss
CRBPCorbus Pharmaceuticals Holding
Buy$80.00Jul 2024−78.4%Miss
ZURAZura Bio Limited Class A Ordinary Shares
Buy$21.00May 2024−70.4%Miss
MCRBSeres Therapeutics Inc
Buy$4.00May 2024−59.3%Miss
CRVSCorvus Pharmaceuticals Inc
Buy$8.00May 2024+66.5%Hit
CMMBChemomab Therapeutics Ltd DRC
Buy$6.00May 2024+41.5%Miss
CLRBCellectar Biosciences Inc
Buy$12.00Mar 2024−91.7%Miss
CRVSCorvus Pharmaceuticals Inc
Buy$7.00Mar 2024+126.6%Hit
MCRBSeres Therapeutics Inc
Buy$5.00Mar 2024−28.4%Miss
MCRBSeres Therapeutics Inc
Buy$9.00Jan 2024−42.0%Miss
PMVPPmv Pharmaceuticals Inc
Buy$15.00May 2023−74.6%Miss
CMMBChemomab Therapeutics Ltd DRC
Buy$7.00Apr 2023−69.9%Miss
ANTXAN2 Therapeutics Inc
Buy$24.00Mar 2023−76.9%Miss
MBRXMoleculin Biotech Inc
Buy$5.00Mar 2023−79.2%Miss
PMVPPmv Pharmaceuticals Inc
Buy$15.00Mar 2023−83.4%Miss
EVAXEvaxion Biotech AS
Buy$11.00Nov 2022−64.1%Miss
MBRXMoleculin Biotech Inc
Buy$14.00Jul 2022−68.7%Miss
CLRBCellectar Biosciences Inc
Buy$5.50Jul 2022−67.2%Miss
EVAXEvaxion Biotech AS
Buy$16.00Jul 2022−51.7%Miss
PMVPPmv Pharmaceuticals Inc
Buy$33.00Jun 2022−48.9%Miss
CMMBChemomab Therapeutics Ltd DRC
Buy$20.00Mar 2022−62.5%Miss
Go to

Jeff Jones: analyst track record FAQ

Is Jeff Jones a good stock analyst?

Yes, by track record. Jeff Jones ranks number 172 of 347 of the analysts Bullish Whales scores, with a BW Score of 30 out of 100. Past results do not guarantee future ones.

What is Jeff Jones's win rate?

Jeff Jones's win rate is 32%. Across 35 scored calls, their rated stocks beat their sector 32% of the time over the next 12 months. On a typical call they returned −6.8% more than the sector.

What stocks and sectors does Jeff Jones cover?

Jeff Jones covers 13 companies, with the most coverage in Healthcare. See the ratings table above for every scored call and its outcome.

Are Jeff Jones's price targets accurate?

Jeff Jones's price targets are reached within 12 months 25% of the time. The base rate across all analysts Bullish Whales tracks is about 43 percent.

How accurate are Wall Street analyst price targets?

Most analyst price targets are not reached on schedule. Across every target Bullish Whales scores, the stock reaches the target within 12 months only about 43 percent of the time, which is why it helps to compare hit rates analyst by analyst.

Should I follow Jeff Jones's stock ratings?

Their track record is strong, but no analyst is right every time. Follow the long-term track record rather than any single rating, size your positions to your own risk, and treat this as research, not investment advice.

How does Bullish Whales score analyst accuracy?

Bullish Whales scores every rating on real prices. We enter at the closing price on or after the call date, with no look-ahead, then measure the 12-month return above the stock's sector ETF and check whether the price target was reached. Scores are pulled toward the population average and corrected for testing thousands of analysts at once, so they reflect repeatable skill rather than luck.

How does Jeff Jones rank among Wall Street analysts?

Jeff Jones ranks number 172 of 347 by BW Score. We rank analysts by their realized 12-month sector-excess return and require a minimum number of calls so a few lucky picks cannot reach the top.

Browse the full analyst leaderboardHow analyst accuracy is scored

Every score, Win %, PT Hit % and rank is an estimate Bullish Whales calculates from its own data and may not be 100% accurate or complete. Returns are measured in excess of each rated stock's own sector over the 12 months after each call. Past performance does not guarantee future results, and nothing here is a recommendation to buy or sell any security.

v1.0.30